Biohaven Ltd. has entered into a $600 million non-dilutive funding agreement with Oberland Capital, with an initial $250 million tranche expected by April 30, 2025.
Biohaven Ltd. reported its third quarter 2024 financial results, highlighting significant progress in its clinical trials, including positive outcomes for troriluzole in treating spinocerebellar ataxia (SCA) and advancements in its pipeline for migraine, neuropathic pain, and other diseases. The company also detailed its financial position and upcoming milestones.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.